Ventripoint Diagnostics Ltd. (TSX-V:VPT, OTC:VPTDF) announced today that its strategic partner, Lishman Global Inc., has formally submitted the Company's VMS+™ 4.0 system to China's National Medical Products Administration (NMPA) for regulatory approval. The submission has qualified for the NMPA's “green channel” pathway, an expedited review process designed for innovative medical technologies addressing significant clinical needs.
The green channel designation is expected to streamline the regulatory timeline and facilitate faster market access. This milestone is a key component of Ventripoint's global expansion strategy and reflects growing demand for advanced, accessible cardiac imaging solutions in China, one of the world's largest healthcare markets.
Cardiovascular disease is the leading cause of mortality in China, affecting an estimated 330 million patients. Echocardiography is the most widely used cardiac imaging modality due to its cost-effectiveness, portability, and scalability across urban and rural settings. However, variability in image interpretation and limited access to advanced imaging like MRI have created a strong need for AI-driven tools that improve diagnostic accuracy and workflow efficiency.
Ventripoint's VMS+™ 4.0 addresses this need by providing MRI-equivalent volumetric measurements using standard 2D echocardiography. Powered by the Company's proprietary Knowledge Based Reconstruction technology, the platform enables clinicians to assess all four chambers of the heart with high accuracy, supporting diagnosis and management of conditions such as congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
“We are excited to take this important step toward bringing VMS+™ 4.0 to the Chinese market,” said Paul Gibson, Chief Technology Officer of Lishman Global Inc. “Qualification for the NMPA's green channel underscores the clinical relevance and innovation of VMS+™ 4.0 and provides a clear pathway to accelerated adoption. China's scale, combined with its increasing focus on improving cardiovascular outcomes, makes it an ideal environment for this technology.”
“Hitting this regulatory milestone with Lishman Global is a key validation of both our technology and our international strategy,” said Hugh MacNaught, President and Chief Executive Officer of Ventripoint Diagnostics. “China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+™ 4.0 to clinicians and patients more quickly. By enabling more accurate and reproducible cardiac measurements using existing ultrasound infrastructure, VMS+ has the potential to significantly expand access to high-quality cardiac care.”
The implications of this submission are significant for the Chinese healthcare system and the global medical imaging industry. If approved, VMS+™ 4.0 could help standardize cardiac assessments across China's diverse healthcare settings, potentially improving outcomes for millions of patients. For Ventripoint, successful entry into China would represent a major revenue opportunity and validate the company's AI-driven approach to echocardiography. The expedited green channel review underscores the NMPA's recognition of the technology's clinical value, and analysts will be watching for further updates as the review progresses.
The Company has stated it will provide further updates as the regulatory review process progresses.
